NASDAQ:ZIOP
Delisted
ZIOPHARM Oncology Inc Stock News
$0.80
+0 (+0%)
At Close: Aug 17, 2022
Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway
04:05pm, Monday, 27'th Sep 2021
• Over 50% reduction in personnel
Here's Why Ziopharm Oncology Stock Is Up 18% This Week
09:00am, Friday, 10'th Sep 2021
Recent insider stock purchases were more than a little encouraging.
Is the Options Market Predicting a Spike ZIOPHARM (ZIOP) Stock?
10:14am, Wednesday, 08'th Sep 2021
Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.
ZIOP Stock: Over 45% Increase Explanation
12:12pm, Tuesday, 07'th Sep 2021
The stock price of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) increased by over 45% during intraday trading. This is why it happened.
Why Shares of Ziopharm Oncology Jumped on Wednesday
04:36pm, Wednesday, 01'st Sep 2021
The company hopes to develop cancer treatments based on individualized gene therapies, and has two promising pipeline candidates.
Ziopharm Oncology to Participate in September Investor Conferences
04:05pm, Wednesday, 01'st Sep 2021
BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer o
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions
08:30am, Monday, 30'th Aug 2021
Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles
ZIOPHARM Oncology's (ZIOP) CEO Heidi Hagen on Q2 2021 Results - Earnings Call Transcript
09:48pm, Monday, 09'th Aug 2021
ZIOPHARM Oncology's (ZIOP) CEO Heidi Hagen on Q2 2021 Results - Earnings Call Transcript
Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021
04:30pm, Monday, 26'th Jul 2021
BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provi
Ziopharm Oncology to Participate in Upcoming Conferences
04:05pm, Monday, 24'th May 2021
BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor
Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting
04:05pm, Wednesday, 19'th May 2021
– Highlighted distinctive cellular therapy program, market opportunity and value proposition
ZIOPHARM Oncology, Inc.'s (ZIOP) Interim CEO Heidi Hagen on Q1 2021 Results - Earnings Call Transcript
10:33pm, Thursday, 06'th May 2021
ZIOPHARM Oncology, Inc.'s (ZIOP) Interim CEO Heidi Hagen on Q1 2021 Results - Earnings Call Transcript
Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting
09:00am, Wednesday, 07'th Apr 2021
Adds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancers Adds to growing body of published research supporting the dev
Why Ziopharm Oncology Stock Is Sinking Today
11:43am, Friday, 12'th Mar 2021
Shares are dropping after an analyst's downgrade.
Why Ziopharm Oncology Stock Is Jumping Today
12:22pm, Friday, 26'th Feb 2021
Investors reacted positively to FDA clearance to begin a clinical study and Ziopharm's CEO change.
